Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARPO
Previous Symbol
CUSIPN/A
Phone513-985-1920
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees25
Outstanding Shares40,580,000
Market Cap$105.87 million
OptionableN/A
Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions
What is Aerpio Pharmaceuticals' stock symbol?
Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."
How were Aerpio Pharmaceuticals' earnings last quarter?
Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) released its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.02. The firm earned $1.33 million during the quarter. View Aerpio Pharmaceuticals' Earnings History.
What price target have analysts set for ARPO?
3 brokers have issued 12 month price targets for Aerpio Pharmaceuticals' stock. Their predictions range from $9.00 to $10.00. On average, they anticipate Aerpio Pharmaceuticals' share price to reach $9.6667 in the next year. This suggests a possible upside of 376.2% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals.
What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerpio Pharmaceuticals.
What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (10/16/2018)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $350M, which includes a discounted cash flow-based asset value for AKB-9778 and AKB-4924, using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 30% and 10%, respectively. Risks include, but are not limited to: (1) failure of AKB-9778 or AKB-4924 in clinical trials; (2) failure of AKB-9778 or AKB-4924 to secure regulatory approval; (3) failure of AKB-9778 or AKB-4924 to achieve commercial success due to market size, penetration rate, or competition; and (4) dilution risk." (8/15/2018)
Who are some of Aerpio Pharmaceuticals' key competitors?
Some companies that are related to Aerpio Pharmaceuticals include Verastem (VSTM), Xeris Pharmaceuticals (XERS), Corbus Pharmaceuticals (CRBP), Theratechnologies (THERF), Odonate Therapeutics (ODT), Achillion Pharmaceuticals (ACHN), Minerva Neurosciences (NERV), Zymeworks (ZYME), ZEALAND PHARMA/S (ZEAL), Cytokinetics (CYTK), Aclaris Therapeutics (ACRS), Keryx Biopharmaceuticals (KERX), Zafgen (ZFGN), Urovant Sciences (UROV) and Merus (MRUS).
Who are Aerpio Pharmaceuticals' key executives?
Aerpio Pharmaceuticals' management team includes the folowing people:
- Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
- Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
- Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
- Dr. Stephen J. Hoffman, CEO & Director (Age 64)
- Mr. Michael W. Rogers, Chief Financial Officer (Age 58)
How do I buy shares of Aerpio Pharmaceuticals?
Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerpio Pharmaceuticals' stock price today?
One share of ARPO stock can currently be purchased for approximately $2.03.
How big of a company is Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals has a market capitalization of $105.87 million. Aerpio Pharmaceuticals employs 25 workers across the globe.
What is Aerpio Pharmaceuticals' official website?
How can I contact Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]
MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
